UBS Group’s Ocular Therapeutix OCUL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $15.2M | Buy |
1,551,001
+30,370
| +2% | +$275K | ﹤0.01% | 2973 |
|
|
2026
Q1 | $12.9M | Buy |
1,520,631
+275,687
| +22% | +$2.63M | ﹤0.01% | 3080 |
|
|
2025
Q4 | $15.1M | Sell |
1,244,944
-3,322
| -0.3% | -$40.4K | ﹤0.01% | 2868 |
|
|
2025
Q3 | $14.6M | Sell |
1,248,266
-716,885
| -36% | -$8.57M | ﹤0.01% | 2906 |
|
|
2025
Q2 | $18.2M | Buy |
1,965,151
+630,212
| +47% | +$4.93M | ﹤0.01% | 2462 |
|
|
2025
Q1 | $9.79M | Buy |
1,334,939
+458,393
| +52% | +$3.52M | ﹤0.01% | 3062 |
|
|
2024
Q4 | $7.49M | Buy |
876,546
+191,770
| +28% | +$1.87M | ﹤0.01% | 3388 |
|
|
2024
Q3 | $5.96M | Sell |
684,776
-63,957
| -9% | -$527K | ﹤0.01% | 2891 |
|
|
2024
Q2 | $5.12M | Buy |
748,733
+265,227
| +55% | +$1.64M | ﹤0.01% | 2855 |
|
|
2024
Q1 | $4.4M | Buy |
483,506
+392,673
| +432% | +$2.79M | ﹤0.01% | 3106 |
|
|
2023
Q4 | $405K | Buy |
90,833
+37,259
| +70% | +$110K | ﹤0.01% | 5262 |
|
|
2023
Q3 | $168K | Sell |
53,574
-76,377
| -59% | -$313K | ﹤0.01% | 5479 |
|
|
2023
Q2 | $671K | Buy |
129,951
+128,674
| +10,076% | +$765K | ﹤0.01% | 4567 |
|
|
2023
Q1 | $6.73K | Hold |
1,277
| – | – | ﹤0.01% | 7892 |
|
|
2022
Q4 | $3.59K | Buy |
1,277
+277
| +28% | +$917 | ﹤0.01% | 9486 |
|
|
2022
Q3 | $4K | Sell |
1,000
-341,228
| -100% | -$1.72M | ﹤0.01% | 9378 |
|
|
2022
Q2 | $1.38M | Buy |
342,228
+307,344
| +881% | +$1.16M | ﹤0.01% | 3443 |
|
|
2022
Q1 | $173K | Sell |
34,884
-60,006
| -63% | -$333K | ﹤0.01% | 5481 |
|
|
2021
Q4 | $661K | Sell |
94,890
-231,738
| -71% | -$1.8M | ﹤0.01% | 4751 |
|
|
2021
Q3 | $3.27M | Sell |
326,628
-258,165
| -44% | -$2.9M | ﹤0.01% | 3132 |
|
|
2021
Q2 | $8.29M | Buy |
584,793
+33,929
| +6% | +$516K | ﹤0.01% | 2204 |
|
|
2021
Q1 | $9.04M | Sell |
550,864
-69,232
| -11% | -$1.33M | ﹤0.01% | 2040 |
|
|
2020
Q4 | $12.8M | Buy |
620,096
+483,347
| +353% | +$7.18M | ﹤0.01% | 1666 |
|
|
2020
Q3 | $1.04M | Sell |
136,749
-27,847
| -17% | -$231K | ﹤0.01% | 3607 |
|
|
2020
Q2 | $1.37M | Buy |
164,596
+131,706
| +400% | +$873K | ﹤0.01% | 3231 |
|
|
2020
Q1 | $163K | Sell |
32,890
-19,805
| -38% | -$97.8K | ﹤0.01% | 4885 |
|
|
2019
Q4 | $208K | Buy |
52,695
+26,812
| +104% | +$93.2K | ﹤0.01% | 5580 |
|
|
2019
Q3 | $79K | Buy |
25,883
+25,383
| +5,077% | +$113K | ﹤0.01% | 5909 |
|
|
2019
Q2 | $2K | Hold |
500
| – | – | ﹤0.01% | 7625 |
|
|
2019
Q1 | $2K | Sell |
500
-1,423
| -74% | -$5.72K | ﹤0.01% | 7458 |
|
|
2018
Q4 | $8K | Sell |
1,923
-13,613
| -88% | -$75K | ﹤0.01% | 7351 |
|
|
2018
Q3 | $107K | Sell |
15,536
-15,734
| -50% | -$98.7K | ﹤0.01% | 5544 |
|
|
2018
Q2 | $211K | Buy |
31,270
+23,770
| +317% | +$163K | ﹤0.01% | 4903 |
|
|
2018
Q1 | $49K | Buy |
7,500
+1,558
| +26% | +$8.77K | ﹤0.01% | 5728 |
|
|
2017
Q4 | $26K | Sell |
5,942
-2,243
| -27% | -$11.5K | ﹤0.01% | 6355 |
|
|
2017
Q3 | $51K | Buy |
8,185
+3,035
| +59% | +$19.5K | ﹤0.01% | 5780 |
|
|
2017
Q2 | $48K | Sell |
5,150
-2,406
| -32% | -$23.3K | ﹤0.01% | 5673 |
|
|
2017
Q1 | $70K | Buy |
7,556
+4,243
| +128% | +$35.3K | ﹤0.01% | 5289 |
|
|
2016
Q4 | $28K | Sell |
3,313
-2,660
| -45% | -$20.6K | ﹤0.01% | 6293 |
|
|
2016
Q3 | $41K | Buy |
5,973
+2,111
| +55% | +$12.9K | ﹤0.01% | 5679 |
|
|
2016
Q2 | $19K | Buy |
3,862
+2,362
| +157% | +$23.4K | ﹤0.01% | 6350 |
|
|
2016
Q1 | $14K | Sell |
1,500
-4,588
| -75% | -$34.8K | ﹤0.01% | 6453 |
|
|
2015
Q4 | $57K | Buy |
6,088
+2,388
| +65% | +$25.8K | ﹤0.01% | 5707 |
|
|
2015
Q3 | $52K | Buy |
3,700
+3,525
| +2,014% | +$70.8K | ﹤0.01% | 5802 |
|
|
2015
Q2 | $4K | Sell |
175
-603
| -78% | -$14.9K | ﹤0.01% | 7981 |
|
|
2015
Q1 | $33K | Buy |
778
+216
| +38% | +$7.1K | ﹤0.01% | 6458 |
|
|
2014
Q4 | $13K | Buy |
+562
| New | +$9.45K | ﹤0.01% | 8149 |
|
Other funds holding OCUL
DTC
ACA
SR
VA
LGM
UBS Group's OCUL Position: Q2 2026 in Review
UBS Group increased its Ocular Therapeutix (OCUL) stake by 2% in Q2 2026, buying an estimated $275K and bringing the position to 1,551,001 shares worth $15.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2973.
UBS Group first reported a position in OCUL in Q4 2014 and has held it in 47 quarters since. The position peaked at $18.2M in Q2 2025. 261 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.
- UBS Group held 1,551,001 shares of Ocular Therapeutix worth $15.2M as of Q2 2026.
- UBS Group bought 30,370 Ocular Therapeutix shares in Q2 2026, an estimated $275K.
- Ocular Therapeutix made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2973 holding.
- UBS Group first reported a position in Ocular Therapeutix in Q4 2014 and has held it in 47 quarters since.
- UBS Group's Ocular Therapeutix position peaked at $18.2M in Q2 2025.
- 261 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.